

HERE



Value-Based Arrangements for Gene and Cell Therapies

May 3, 2024

Michael Heifetz Campaign for Transformative Therapies

Campaign for Transformative Therapies

- Coalition of Payers, Patients, and BIO
- Promoting Sustainable Access Through Value Based Arrangements (VBAs)
- Achieving Balance: Access, Cost, and Outcomes
- State-based Solutions





Why VBAs?

- Promote Meaningful Access & Equity
- Construct a Sustainable Reimbursement Strategy:

Share RiskHold Manufacturers Accountable

- Voluntary for Both Payers & Manufacturers
- Measure Outcomes
- Improve Patient Lives





Truly Transformative Therapies...

- Casgevy Sickle Cell Disease
- Lyfgenia Sickle Cell Disease
- Zolgensma Spinal Muscular Atrophy (Under Age 2)
- Luxterna Hereditary Retinal Dystrophy
- Hemegenix Hemophilia B
- Roctavian Hemophilia A






LIMITLESS POSSIBILITY LIVES HERE

Rapidly Changing Environment

- 2017: First gene therapy approved (Luxturna), multiple cell therapies approved
- 2019: Zolgensma (SMA) brings total to 2 gene therapies & multiple cell therapies
- 2022: 3 more approvals
- 2023: 5 approvals, including 2 for Sickle Cell Disease & 1 for Hemophilia A
- 2024: 2 approvals already
- 60+ expected to be approved for US market by 2030 (National Institutes of Health)
- As of May 3, 2024: 2,292 gene or cell therapies in development (American Society of Cell and Gene Therapy)

SUSTAINABLE MODELS NEEDED TO MATCH THIS ENVIRONMENT





LIMITLESS POSSIBILITY LIVES HERE



Enables a Path Forward Without a Mandate

State Plan Amendments (SPAs)

- Multiple others have submitted a SPA (CA) or are moving forward (MN, WI)
- 21 States and Washington, D.C.: AL, AZ, AR, CO, DC*, GA, IL, IN, LA, MA, MI, MO, NC, ND, NY, OH, OK, PA, TX, UT, VT, WA



